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withaferin A inhibit the chaperone activity of
peroxiredoxin I†
Qian Zhao,a Yu Ding,b Zhangshuang Deng,c On-Yi Lee,a Peng Gao,d Pin Chen,a
Rebecca J. Rose,e Hong Zhao,f Zhehao Zhang,a Xin-Pei Tao,a Albert J. R. Heck,e
Richard Kaod and Dan Yang*a
Peroxiredoxin I (Prx I) plays an important role in cancer development and inflammation. It is a dual-
functional protein which acts as both an antioxidant enzyme and a molecular chaperone. While there
have been intensive studies on its peroxidase activity, Prx I's chaperone activity remains elusive, likely due
to the lack of chaperone inhibitors. Here we report that natural product triptolide selectively inhibits the
chaperone activity of Prx I, but not its peroxidase activity. Through direct interaction with corresponding
cysteines, triptolide triggers dissociation of high-molecular-weight oligomers of Prx I, and thereby
inhibits its chaperone activity in a dose-dependent manner. We have also identified celastrol and
withaferin A as novel Prx I chaperone inhibitors that are even more potent than triptolide in the
chaperone activity assay. By revealing the exact molecular mechanisms of interaction and inhibition, the
current study provides the first Prx I chaperone inhibitors as promising pharmacological tools for
modulating and dissecting the chaperone function of Prx I.Introduction
Essentially every cellular process relies on close coordination of
complex protein networks, in which a single protein can be
involved in various pathways by playing different functional
roles.1,2 To elucidate the contributions of a protein with
multiple functions in regulating diverse cellular processes,
methods are required to study each function of the protein
independently and orthogonally. Compared with genetic
manipulation, such as the knockdown approach, small-mole-
cule inhibitors offer several advantages by modulating their
target proteins with rapid onset, allowing precise temporal
control over protein functions.3–5More importantly, it is feasible
that one function of a protein is inhibited while all other
functions remain unaltered providing that selective inhibitorsiology, Department of Chemistry, The
. E-mail: yangdan@hku.hk
hanghai, China
Research and Development, College of
hina Three Gorges University, Yichang,
y of Hong Kong, Hong Kong, China
and Utrecht Institute for Pharmaceutical
oteomics Centre, The Netherlands
ersity of Hong Kong, Hong Kong, China
ESI) available: Chemical synthesis and
Fig. S1–S10; Table S1–S3. See DOI:are available.6 This is particularly valuable in exploring complex
cellular mechanisms of proteins with multiple functions.
Peroxiredoxin I (Prx I) is a dual-functional protein that can
act as both an antioxidant enzyme and molecular chaperone,
depending on its oligomeric states.7 In the form of homo-
dimers, Prx I functions as a peroxidase, catalysing removal of
H2O2.7,8 Prx I is also present in the form of homodecamers or
higher-order oligomers to function as a molecular chaperone
that prevents client proteins from stress-induced aggrega-
tion.9,10 Recent studies reveal that, depending on its oligomeric
structure or chaperone activity, Prx I interacts with essential
signalling molecules, such as p53,11 NF-kB12 and TLR4,13 and
thus plays an important role in normal cell physiology and
disease pathology. However, the understanding of Prx I as a
molecular chaperone and its potential to become a therapeutic
target is limited by a lack of chaperone inhibitors. While ade-
nanthin has been identied as an inhibitor of the peroxidase
activity of Prx I,14 there is an unmet need for specic modulators
of the Prx I chaperone activity.
Here we report the identication of triptolide (TL), a bioactive
natural product, as a selective inhibitor of the chaperone activity
of Prx I. TL specically binds to Cys83 and Cys173, which play
crucial roles in maintaining Prx I's decameric structure and
chaperone activity. Using a competition assay based on a uo-
rescent triptolide derivative, the natural products celastrol (Cel)
and withaferin A (WA) have also been found to interact with Prx
I.Mass spectrometry analyses indicate that Cel andWA share the
same mechanism with TL in binding to Prx I. The present studyThis journal is © The Royal Society of Chemistry 2015
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View Article Onlinenot only identies three novel chaperone inhibitors of Prx I, but
also demonstrates that small molecules, as promising pharma-
cological tools, can modulate a multi-functional protein.Scheme 1 General synthetic routes to Biotin-TL and Cy3-TL.
Reagents and conditions: (a) cerium(VI) ammonium nitrate, MeCN,
0 C, 99%; (b) IBX, acetone, reflux, 98%; (c) AlCl3, MeCN, reflux, 100%;
(d) Sc(OTf)3, NIS, AcOH, rt, 82%; (e) THPOCH2C^CH, PdCl2(PPh3)2,
CuI, Et3N, THF, 35 C, 97%; (f) H2, Pd/C, EtOH, 40–50 C, 100%; (g)
TsOH$H2O, MeOH, rt, 95%; (h) NaBH4, EtOH, CH2Cl2, 0 C, 99%; (i)
NaIO4, MeOH, H2O, rt, 80%; (j) CF3COCH3, OXONE, NaHCO3, CH3CN,
Na2(EDTA), 0 C; (k) p-nitrophenylchloroformate, pyridine, CH2Cl2, rt,
the yield of 14was 13% from 10; (l) DMAP, Et3N, CH2Cl2/MeOH, rt, 24%;
(m) K-selectride, THF, 40 C, 39%; (n) DMAP, Et3N, CH2Cl2, rt, 85%; (o)
K-selectride, anhydrous THF,78 C; (p) 30% TFA in CH2Cl2 (v/v), rt; (q)
Cy3-NHS, CH2Cl2, DMAP, rt, 42%.Results
Chemical synthesis of probes Biotin-TL and Cy3-TL
We have been working on the chemical synthesis and biological
mechanism of TL,15,16 a bioactive natural product, whose
derivatives have entered human clinical trials for cancers and
autosomal kidney diseases.17,18 Meanwhile, TL's cellular mech-
anism has also attracted much attention.19–22 To further eluci-
date its cellular mechanism, we synthesized a biotinylated
triptolide (Biotin-TL) and a uorescent cyanine-labelled tripto-
lide (Cy3-TL) to enrich and visualize triptolide-binding proteins,
respectively (Scheme 1). More details on the synthesis can be
found in the ESI.†
Identication of peroxiredoxin I as a direct binding protein of
triptolide
We rst carried out an experiment to search for binding
protein(s) of triptolide using the chemical probes synthesized.
Cell lysates were incubated with Biotin-TL, and proteins were
puried with streptactin-conjugated agarose beads, followed by
SDS-PAGE analysis and silver staining (Fig. 1a). One band with a
molecular mass of around 23 kDa was observed in the protein
sample enriched by Biotin-TL, but not by biotin. This band was
observed reproducibly using different cell lines (Fig. S1†).
Furthermore, the protein band can be competed away by excess
triptolide prior to enrichment by Biotin-TL (Fig. S2†). MALDI-
TOFMS analysis of the protein band revealed the identity of this
protein as Prx I (Fig. S3†).
To validate the specicity of the interaction between Prx I
and triptolide, a competition binding assay was performed.
Recombinant Prx I was rst incubated with the indicated
concentration of TL and then with uorescent probe Cy3-TL.
The resultant mixture was subjected to SDS-PAGE and in-gel
uorescence scanning. Co-migration of Cy3-TL and Prx I
protein on a denaturing gel suggests a covalent linkage between
them. As shown by the relative uorescence intensity, the Prx
I–TL interaction was sensitive to competition with excess TL
(Fig. 1b).
As a negative control, recombinant thioredoxin and thio-
redoxin reductase incubated with Cy3-TL did not give anyThis journal is © The Royal Society of Chemistry 2015uorescence, suggesting that they cannot form a covalent
linkage with Cy3-TL, even though they possess more reactive
cysteine residues (Fig. S4†).23Structural characterization of Prx I–TL and conrmation of
the binding sites
To further pin down the exact TL-binding peptides or binding
site(s), recombinant Prx I was incubated with TL, and the
resulting mixture was subjected to LC-MS/MS analysis. The m/zChem. Sci., 2015, 6, 4124–4130 | 4125
Fig. 1 Identification of peroxiredoxin I as a direct binding protein of
triptolide. (a) A silver-stained gel of pull-down products of Biotin-TL or
biotin. MDCK cell lysate was incubated with 5 mM biotin or Biotin-TL.
Proteins were then purified using streptactin-conjugated agarose
beads, followed by SDS-PAGE analysis. The arrow indicates a band
confirmed as Prx I. (b) In-gel fluorescence analysis of recombinant Prx I
after incubation with Cy3-TL in the absence or presence of TL
pretreatment.
Fig. 2 Structural characterization of Prx I–TL and confirmation of the
binding sites. (a) MS/MS analysis of the Cys173-containing tryptic
peptide after recombinant Prx I was incubated with TL, followed by
trypsin digestion. The asterisk indicates the residue bound by TL; red
labels show ions that display a mass shift corresponding to TL. (b) 1 mM
recombinant Prx I and its mutants were incubated with 100 nM Biotin-
TL at 4 C for 3 h, followed by Western blotting for biotin or Prx I. (c)
Native ESI-MS analysis of the monomer (upper) and dimer (lower) of
the Prx I–TL complex. 10 mM recombinant Prx I was incubated with
vehicle or 40 mM TL at 4 C overnight before analysis. Schematic
diagrams show interactions between TL and the Prx I monomer/dimer.
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View Article Onlineof the Cys173-containing peptide HGEVCPAGWKPGSD-
TIKPDVQK had a mass increase of 360.2 Da, which is consistent
with the calculated value for the addition of one TL molecule to
this peptide. Further fragmentation of this peptide produced a
series of b/y-ion fragments. According to the MS/MS spectrum,
only the Cys173-containing fragments (Fig. 2a, b5-b10 and b14-
b16, marked in red) display a 360.2 Da mass shi, suggesting
Cys173 is the covalently modied residue.
Given that Cys173 can be modied by triptolide, we next
examined whether other cysteine residues are involved in the
Prx I–triptolide interaction. In our experiment, wild-type and
mutant Prx I recombinant proteins were incubated with Biotin-
TL and subsequently resolved by SDS-PAGE. Co-migration of
proteins and Biotin-TL was detected by immunoblot with
streptavidin-HRP. When Cys83 and Cys173 were simultaneously
replaced with serine residues, the interactions between Prx I
and Biotin-TL were totally abolished (Fig. 2b and S5†). This
result illustrates that both Cys83 and Cys173 play important roles
in the formation of the Prx I–TL complex.
This conclusion was further supported by the investigation of
the Prx I–TL complex in different oligomeric statuses using
native mass spectrometry (MS). Native MS allows large intact
protein homo/hetero-complexes to be analyzed with high
sensitivity and resolution. As shown in Fig. 2c, there were two
TL-binding sites in monomeric Prx I, whereas the dimeric form
of Prx I bound to two TL molecules instead of four. Considering4126 | Chem. Sci., 2015, 6, 4124–4130 This journal is © The Royal Society of Chemistry 2015
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View Article Onlinethat a Prx I dimer is formed through an intermolecular disul-
phide bond between Cys173 and Cys52,24 it is reasonable that
Cys173 is no longer available to bind to TL (Fig. 2c), leading to the
loss of two reactive sites in a Prx I dimer. This is consistent with
our aforementioned observation that Cys173 is one of the two
reactive sites for TL. Meanwhile, the other binding site, Cys83,
should not differ signicantly in its monomeric or dimeric
forms, and thereby becomes the sole site for the TL interaction.Fig. 3 Effects of TL on the biological activity of Prx I. (a) Peroxidase
activity assay of 1 mM Prx I with indicated treatment. (b) Gel filtration
analysis of 40 mM Prx I after overnight incubation with the indicated
concentration of TL at 4 C. (c) Chaperone activity assay of Prx I in the
presence of TL. 2.5 mM recombinant Prx I was incubated with TL
overnight at 4 C. Light scattering of 10 mM client protein MDH was
monitored under heating at 45 C for 30 min.Functional characterization of the interaction between Prx I
and TL
We next examined the functional consequence of this TL-Prx I
interaction. First, we measured the peroxidase activity of Prx I in
the presence or absence of triptolide. Adenanthin (AND) was
reported to inhibit Prx I's peroxidase activity at 1 mM.14 In our
assay, we used 80 mM AND as a positive control to signicantly
inhibit the Prx I peroxidase activity. However, treatment with TL
at the same concentration (80 mM) did not suppress the perox-
idase activity of recombinant Prx I (Fig. 3a and S6†).
The knowledge of the binding residues of TL on Prx I guided
us to investigate Prx I's oligomeric state because both Cys83 and
Cys173 play important roles in regulating the oligomeric struc-
tures of Prx I. 40 mM recombinant Prx I was incubated with TL at
protein-compound molar ratios of 5 : 1, 1 : 2, and 1 : 5. Subse-
quent size-exclusion chromatographic analyses were performed
and revealed that TL induced dramatic Prx I decamer dissoci-
ation, and the proportion of tetramers and dimers increased in
a dose-dependent manner (Fig. 3b). This observation is
consistent with a previous report that glutathionylation of Cys83
and Cys173 induces dissociation of Prx I decamers.25
There is a growing body of evidence suggesting that higher-
ordered Prx I oligomers function as crucial molecular chaper-
ones to protect client molecules from stress-induced aggrega-
tion.26,27 Hence, we employed a chaperone assay to investigate
whether TL inuences the chaperone activity of Prx I. As
previously described, Prx I is able to protect its client protein
malate dehydrogenase (MDH) from thermal aggregation.28 To
test TL's effect, recombinant Prx I was incubated with TL over-
night at 4 C. Then, MDHwas added to themixture immediately
before the assay. The radii of the particles were monitored by
light scattering, which serves as an indicator of MDH aggrega-
tion, during heating at 45 C for 30 min. In one control exper-
iment, aggregation of MDH remained the same in the absence
or presence of TL, suggesting that TL does not inuence MDH
directly (Fig. S9†). In the other control experiment, TL-treated
Prx I did not exhibit obvious aggregation under heating, indi-
cating that TL does not directly induce Prx I aggregation
(Fig. S10†). However, when MDH was mixed with TL-treated Prx
I, instead of DMSO-treated Prx I, enhanced aggregation was
observed, suggesting suppression of Prx I's chaperone activity
by TL in a dose-dependent manner (Fig. 3c). We noticed that
TL's inhibition of the Prx I chaperone activity was partial.
Actually, this observation is consistent with the partial
engagement of TL with Prx I, as shown by native MS analysis
(Fig. 2c). This became the initial motivation for us to screen for
other potent inhibitors of Prx I.This journal is © The Royal Society of Chemistry 2015Identication and validation of novel Prx I inhibitors
Finally, we carried out a competition experiment, employing
Cy3-TL as a reporter to screen TL derivatives and other natural
products as Prx I inhibitors (Fig. 4a). Recombinant Prx I was rst
incubated with an excess of the individual compounds, andChem. Sci., 2015, 6, 4124–4130 | 4127
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View Article Onlinethen incubated with Cy3-TL before being subjected to SDS-
PAGE and an in-gel uorescence scan. While triptonide (TN), a
naturally occurring TL analogue, competed away Cy3-TL, the
other analogue 12-epitriptriolide (eTL) could not. Among those
natural products that we tested, WA and Cel competed away
Cy3-TL (Fig. 4b). This result indicates that TN, WA, and Cel
covalently modied Prx I, while eTL failed to interact with Prx I.
Tandem mass spectrometry analysis of the WA-PrxI complex
demonstrated that WA binds to Prx I also at residues Cys83 and
Cys173 (Fig. 4d and S8†).
Next, we investigated Cel and WA's effect on the chaperone
activity of Prx I. As with TL, Cel andWA did not directly increase
the aggregation of MDH or Prx I under heating, as shown inFig. 4 Identification and validation of novel Prx I chaperone inhibitors.
rescence analysis of recombinant Prx I after incubation with Cy3-TL in t
analysis of the monomer of (left) Prx I and (right) the Prx I–WA complex. 1
overnight before analysis. (d) LC-MS/MS analysis of the Cys173-containing
overnight followed by trypsin digestion. The asterisk indicates the cyste
identified to bind to WA. (e) Chaperone activity assay of Prx I in the p
incubated with TL overnight at 4 C. Light scattering of 10 mM client pro
4128 | Chem. Sci., 2015, 6, 4124–4130control experiments (Fig. S9 and S10†). Incubation of Prx I with
Cel and WA enhanced MDH thermal aggregation signicantly
(Fig. 4e), suggesting suppression of Prx I's chaperone activity.
Interestingly, Cel and WA exhibited even stronger inhibition
than TL in the chaperone assay, consistent with their higher
binding occupancy in Prx I than TL as observed by native MS
(Fig. 4c and S7†).Discussion
Several triptolide-binding proteins have been identied
through biochemical and fractionation approaches. Recently, it
was reported that triptolide binds XPB selectively at its Cys342(a) Chemical structures of withaferin A and celastrol. (b) In-gel fluo-
he absence or presence of the indicated treatment. (c) Native ESI-MS
0 mM recombinant Prx I was incubated with vehicle or 10 mMWA at 4 C
tryptic peptide after recombinant Prx I was incubated with WA at 4 C
ine bound by WA; red labels show the Cys173-containing ions that are
resence of the indicated compounds. 2.5 mM recombinant Prx I was
tein MDH was monitored under heating at 45 C for 30 min.
This journal is © The Royal Society of Chemistry 2015
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View Article Onlinedespite having 14 cysteine residues. The proposed molecular
mechanism involves cysteine reacting with triptolide's C12/C13
epoxide,29 which may also apply to the present study. Another
interesting comparison can be drawn between Prx I and
dCTPP1, which was also found to bind triptolide using bio-
tinylated triptolide probes.21 To identify dCTPP1, Crew's group
synthesized a biotinylated triptolide by modifying the free b
hydroxyl group at C14 of triptolide, which is a known key
functional group for its antitumor activity.30–32 In our study, we
chose to modify triptolide at its C13 site because it showed
minimal inuence on triptolide's anti-cancer activities
(unpublished data). Although the affinity pull-down approach
was used in both cases, it is interesting to note that chemical
derivatization at different sites of small molecules can lead to
identication of different target proteins.
As a member of the peroxiredoxin family (Prxs) which cata-
lyzesH2O2 removal, Prx I is unique in that it canalso function as a
molecular chaperone. The switching of the oligomeric status and
corresponding dual functions of Prx I are modulated by modi-
cations at its cysteines. It is reported that simultaneous gluta-
thionylation of Cys83 and Cys173 induces dissociation of Prx I
decamers. The same event occurs when triptolidemodies these
two residues, as observed in our study. On the contrary, ade-
nanthin, which does not bind to Cys83, does not show a signi-
cant inuence on the oligomeric status of Prx I.14 As chemical
tools, these two natural products with different effects on Prx I
validate the importance of Cys83 in regulating Prx I's oligomeric
status. Given that Cys83 is not conserved in all Prxs, it constitutes
a promising and practical target site for the selectivemodulation
of Prx I’s function. It is worth mentioning that since triptolide
modies Cys83 in Prx I, its uorescent analogue Cy3-TL has
potential as an activity-based probe for screening Prx I ligands or
qualitative/quantitative assay development in future studies.
In addition to triptolide, we have discovered that the natural
products withaferin A and celastrol can also interact with Prx I at
the samesites. It is likely that triptolide,withaferinA, andcelastrol
interact with Prx I through the same mechanism, i.e. by cysteine
alkylation. In contrast to triptonide and triptolide with a C12/C13-
epoxide group as an electrophilic center for cysteine attack,
12-epitriptriolide has a cis-diol structure at the C12/C13 positions,
and hence cannot be alkylated by cysteine residues of Prx I.
Interestingly, withaferin A and celastrol, two bioactive natural
terpenoids, also containelectrophilic carboncenterswhich canbe
attacked by a well-positioned cysteine residue within a binding
pocket. This result indicates the importance of electrophilic
groups of the natural products for the interactions with Prx I.
In the present study, we have identied and validated that
natural products, including triptolide, celastrol, and withaferin
A directly bind to Prx I in a covalent manner. This is, to the best
of our knowledge, the rst identication of natural products
that trigger dissociation of the Prx I decamer and selectively
inhibit its chaperone activity. Although several targets of
celastrol and withaferin A have been reported in the literature, it
is the rst time that Prx I has been identied as a novel target of
celastrol and withaferin A, which may shed light on the
understanding of their biological action.33,34 Our study provides
new chemical probes to perturb Prx I's chaperone activity,This journal is © The Royal Society of Chemistry 2015particularly through interaction with Cys83. Taken together, we
demonstrate that natural products can serve as powerful
chemical probes to precisely modulate their target proteins, and
thus possess great potential to facilitate the biological study of
multifunctional proteins. Considering that triptolide, with-
aferin A, and celastrol share anti-inammatory,35–37 pro-
apoptotic,38–40 and anti-angiogenic activities in common,
further dissection of the correlation between their alkylation of
Prx I and common bioactivities at the cellular level is an
important next step and will be reported in due course.Acknowledgements
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